vasoactive intestinal peptide

Vasoactive Intestinal Peptide (VIP) Guinea pig TFA, a trophic and mitogenic factor, promotes growth in cultured whole embryos and acts as a gastrointestinal hormone, while also indicating potential neurotransmitter functions [1] [2].

Aviptadil (INN) is an analog of vasoactive intestinal polypeptide (VIP) for the treatment of erectile dysfunction.

Aviptadil Acetate (Vasoactive Intestinal Peptide acetate salt) induces pulmonary vasodilation and inhibits the proliferation of vascular SMCs and platelet aggregation. Avitadil acetate can be used for research on pulmonary fibrosis, pulmonary hypertension (PAH), and respiratory failure caused by SARS-CoV-2.

Prepro VIP (111-122), human acetate is a prepro-vasoactive intestinal polypeptide (VIP)–derived peptide, corresponding to residues 111-122.

VIP(6-28)(human, rat, porcine, bovine) acetate is an antagonist of the actions of exogenous vasoactive intestinal peptide (VIP) receptor on cAMP in the superior cervical ganglion (SCG).

[D-p-Cl-Phe6,Leu17]-VIP acetate is a competitive and selective antagonist of vasoactive intestinal peptide (VIP) receptor (IC50 = 125.8 nM).

Prepro VIP (111-122), human is a prepro-vasoactive intestinal polypeptide (VIP)–derived peptide, corresponding to residues 111-122.

Acetyl-(D-Phe2,Lys15,Arg16,Leu27)-VIP(1-7)-GRF(8-27) is a selective antagonist [1] for the vasoactive intestinal peptide 1 (VIP 1) receptor.

Vasomera, a stable, long-acting vasoactive intestinal peptide (VIP) agonist, targets G-protein-coupled VPAC2 receptors and is employed in the study of cardiomyopathy associated with dystrophinopathies [1].

PACAP (1-38) free acid, an endogenous neuropeptide, potently modulates gastrointestinal and neuroendocrine functions. It enhances antral motility, increases somatostatin secretion, and stimulates the release of vasoactive intestinal polypeptide, gastrin releasing peptide, and substance P, while concurrently inhibiting gastrin secretion. Additionally, it augments N-methyl-D-aspartate receptor function and upregulates brain-derived neurotrophic factor expression via RACK1 [1] [2].

PACAP (1-38) free acid TFA, an endogenous neuropeptide, effectively enhances antral motility and somatostatin secretion, while concurrently suppressing gastrin secretion and promoting the release of vasoactive intestinal polypeptide, gastrin releasing peptide, and substance P. Additionally, it amplifies N-methyl-D-aspartate receptor function and brain-derived neurotrophic factor expression via RACK1 [1] [2].

Helospectin I, a neuropeptide belonging to the vasoactive intestinal peptide (VIP) family, exhibits vasodilatory and antihypertensive properties, effectively reducing blood pressure. It was initially isolated from the salivary gland venom of the lizard Heloderma suspectum [1] [2].

Helospectin II, a member of the vasoactive intestinal peptide (VIP) family, exhibits vasodilatory and antihypertensive properties that reduce blood pressure. This neuropeptide was initially isolated from the venom of the salivary glands of the Heloderma suspectum lizard [1] [2].

[K15,R16,L27]VIP(1-7)/GRF(8-27) (acetate) is an acetate salt form of the peptide [K15,R16,L27]VIP(1-7)/GRF(8-27). This compound acts as a selective agonist for the VIP 1 receptor, displaying IC50 values of 2 nM for human VIP 1, 1 nM for rat VIP 1, and 30,000 nM for rat VIP 2 receptors [1]. The peptide's acronym, VIP, stands for Vasoactive Intestinal Polypeptide.

Selective vasoactive intestinal peptide (VIP) receptor antagonist (IC50 = 125.8 nM). Displays no activity on glucagon, secretin or GRF receptors.

PACAP-related peptide (PRP) is an endogenous 29-amino acid peptide that belongs to the secretin/glucagon superfamily of peptides, which includes secretin , glucagon , glucagon-like peptide-1 , GLP-2 , and pituitary adenylate cyclase-activating polypeptide . It is expressed in normal human pancreas and adrenal gland tissue and in some tumors that produce vasoactive intestinal peptide (VIP). PRP (1-29) is secreted by CHO-K1 cells that express human recombinant preproPACAP.

PACAP (1-38), a novel neuropeptide isolated from the bovine hypothalamus is more active than vasoactive intestinal peptide (VIP) in stimulating adenylate cyclase (EC50=7 nM). PACAP 1-38 (10-9 M) increased substance P (SP), gastrin releasing peptide (GRP),

PACAP (6-27) (human, ovine, rat) serves as an antagonist for the PACAP receptor, inhibiting the catecholamine response of the canine adrenal gland to vasoactive intestinal peptide (VIP). This compound holds promise for research into cardiovascular and neurological disorders [1].

[D-p-Cl-Phe6,Leu17]-VIP TFA acts as a competitive and selective antagonist of the vasoactive intestinal peptide (VIP) receptor, exhibiting an IC50 of 125.8 nM. It shows no activity on glucagon, secretin, or growth hormone-releasing factor (GRF) receptors [1] [2] [3].

Prepro VIP (81-122), human is a prepro-vasoactive intestinal polypeptide (VIP) derived peptide, corresponding to residues 81-122.

VIP(6-28)(human, rat, porcine, bovine) is a potent antagonist that effectively counteracts the effects of exogenous vasoactive intestinal peptide (VIP) on cyclic adenosine monophosphate (cAMP) signaling.

[Ac-Tyr1,D-Phe2]GRF 1-29, amide (human) is an analog of GRF and a vasoactive intestinal peptide (VIP) antagonist.